Literatura científica selecionada sobre o tema "Finch, Pruyn and Company, Inc"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Índice
Consulte a lista de atuais artigos, livros, teses, anais de congressos e outras fontes científicas relevantes para o tema "Finch, Pruyn and Company, Inc".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Artigos de revistas sobre o assunto "Finch, Pruyn and Company, Inc"
Burmester, G. R., D. Aletaha, J. Pope, Y. Tanaka, P. Durez, A. Gomez-Centeno, A. Pechonkina et al. "THU0194 CHARACTERISATION OF DEPTH OF RESPONSE, INCLUDING 50% IMPROVEMENT IN ACR COMPONENTS AT WEEK 12 AND REMISSION AT WEEK 24, FOLLOWING TREATMENT WITH FILGOTINIB COMPARED WITH METHOTREXATE OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS". Annals of the Rheumatic Diseases 79, Suppl 1 (junho de 2020): 316.1–317. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2236.
Texto completo da fonteCombe, B., A. Kivitz, Y. Tanaka, D. Van der Heijde, J. A. Simon-Campos, H. S. B. Baraf, U. Kumar et al. "THU0198 EFFICACY AND SAFETY OF FILGOTINIB FOR PATIENTS WITH RHEUMATOID ARTHRITIS WITH INADEQUATE RESPONSE TO METHOTREXATE: FINCH 1 52-WEEK RESULTS". Annals of the Rheumatic Diseases 79, Suppl 1 (junho de 2020): 320–21. http://dx.doi.org/10.1136/annrheumdis-2020-eular.276.
Texto completo da fonteKivitz, A., Y. Tanaka, S. Lee, L. Ye, H. Hu, R. Besuyen e B. Combe. "FRI0128 FILGOTINIB PROVIDED RAPID AND SUSTAINED IMPROVEMENTS IN FUNCTIONAL STATUS, PAIN, HEALTH-RELATED QUALITY OF LIFE, AND FATIGUE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE: RESULTS FROM THE FINCH 1 STUDY". Annals of the Rheumatic Diseases 79, Suppl 1 (junho de 2020): 645.2–646. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2882.
Texto completo da fonteTaylor, P. C., J. Liu, L. Zhuo, Y. Tian, T. Snyder, C. Kim, P. Kheradpour, K. Drake, S. Kim e R. E. Hawtin. "OP0100 MOLECULAR PROFILING OF PERIPHERAL IMMUNE CELL SUBSETS IN PATIENTS WITH RHEUMATOID ARTHRITIS". Annals of the Rheumatic Diseases 79, Suppl 1 (junho de 2020): 65.2–65. http://dx.doi.org/10.1136/annrheumdis-2020-eular.3967.
Texto completo da fonteWalker, D., T. Takeuchi, B. Bartok, S. Rao, I. H. Lee, R. Besuyen, J. E. Gottenberg e M. C. Genovese. "FRI0139 FILGOTINIB PROVIDED RAPID AND SUSTAINED RELIEF OF PAIN AND FATIGUE AND IMPROVED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DMARDS: RESULTS FROM THE FINCH 2 STUDY". Annals of the Rheumatic Diseases 79, Suppl 1 (junho de 2020): 652–53. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2901.
Texto completo da fonteWinthrop, K., M. H. Buch, J. Curtis, G. R. Burmester, D. Aletaha, K. Amano, A. Pechonkina et al. "POS0092 HERPES ZOSTER IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM". Annals of the Rheumatic Diseases 80, Suppl 1 (19 de maio de 2021): 255.1–256. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1408.
Texto completo da fonteCombe, B., T. Matsubara, A. Pechonkina, Y. Tan, Z. Yin, J. Hong, R. Besuyen, A. Gomez-Centeno e M. H. Buch. "POS0657 GEOGRAPHIC VARIATION OF SAFETY IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM". Annals of the Rheumatic Diseases 80, Suppl 1 (19 de maio de 2021): 569.2–570. http://dx.doi.org/10.1136/annrheumdis-2021-eular.643.
Texto completo da fonteGenovese, M. C., K. Winthrop, Y. Tanaka, T. Takeuchi, A. Kivitz, F. Matzkies, L. Ye et al. "THU0202 INTEGRATED SAFETY ANALYSIS OF FILGOTINIB TREATMENT FOR RHEUMATOID ARTHRITIS FROM 7 CLINICAL TRIALS". Annals of the Rheumatic Diseases 79, Suppl 1 (junho de 2020): 324–25. http://dx.doi.org/10.1136/annrheumdis-2020-eular.267.
Texto completo da fonteGottenberg, J. E., M. H. Buch, R. Caporali, G. C. Wright, T. Takeuchi, K. Kalunian, A. Pechonkina et al. "THU0204 A SUBGROUP ANALYSIS OF LOW DISEASE ACTIVITY AND REMISSION FROM PHASE 3 STUDY OF FILGOTINIB IN PATIENTS WITH INADEQUATE RESPONSE TO BIOLOGIC DMARDS". Annals of the Rheumatic Diseases 79, Suppl 1 (junho de 2020): 326–27. http://dx.doi.org/10.1136/annrheumdis-2020-eular.2237.
Texto completo da fonteBuch, M. H., T. Matsubara, B. Combe, A. Pechonkina, Y. Tan, Z. Yin, J. Hong, R. Besuyen e A. Gomez-Centeno. "POS0658 GEOGRAPHIC VARIATION OF EFFICACY IN THE FILGOTINIB RHEUMATOID ARTHRITIS PROGRAM". Annals of the Rheumatic Diseases 80, Suppl 1 (19 de maio de 2021): 570–71. http://dx.doi.org/10.1136/annrheumdis-2021-eular.648.
Texto completo da fonte